



THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENTS

Applicants: J. Henkin, et al.

Serial No.: 09/447,226

Filed: November 22, 1999

Title: PEPTIDE ANTIANGIOGENIC
DRUGS

Case No.: 6356.US.P3

Commissioner for Patents
Washington D.C. 20231

Group Art No.: 1653

Examiner: Lukton, D.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: June 26, 2002

Tanya M. Parent 6/26/02
Tanya M Parent Date

TECH CENTER 1600/2900

JUL 0 8 2002

RECEIVED

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled PEPTIDE ANTIANGIOGENIC DRUGS are the following:

1. Information Disclosure Statement;
2. Form PTO 1449, in duplicate;
3. References as cited on PTO 1449 (10 references); and
4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-3490
Facsimile: (847) 938-2623

Respectfully submitted,
J. Henkin, et al.

Gregory W. Steele
Gregory W. Steele
Registration No. 33,796
Attorney for Applicants

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: J. Henkin, et al.

Serial No.: 09/447,2268

Filed: November 22, 1999

Title: PEPTIDE ANTIANGIOGENIC
DRUGS

Case No.: 6356.US.P3



Group Art No.: 1653

Examiner: Lukton, D.

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:
Commissioner for Patents
Washington, D.C. 20231, on:

Date of Deposit: June 26, 2002

Tanya Parent 6/26/02
Tanya M. Parent Date

TECH CENTER 1600/2900

JUL 08 2002

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after the events recited in 37 C.F.R. § 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final Action or a Notice of Allowance, and is accompanied by the Petition fee of \$180.00 as specified under 37 C.F.R. § 1.97(c). Applicant respectfully petitions and requests that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Applicants hereby authorize the Commissioner to charge the appropriate Petition fee of \$180.00 to Deposit Account No. 01-0025. The Commissioner also is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered. A duplicate of this sheet is enclosed.



23492

ABBOTT LABORATORIES
Telephone: (847) 938-3490
Facsimile: (847) 938-2623

Respectfully submitted,
J. Henkin, et al.

Gregory W. Steele
Gregory W. Steele

Registration No. 33,796
Attorney for Applicants